Olema Pharmaceuticals, Inc. Common Stock
OLMAOlema Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for women’s cancers. Founded to leverage innovative science, the company aims to address unmet medical needs in breast and ovarian cancers through novel approaches and personalized treatments.
Company News
Olema Pharmaceuticals board member Ian T. Clark sold approximately $7.9 million worth of shares (264,800 shares) on December 19, representing a complete exit from his direct equity holdings. The sale followed a 326.5% one-year stock surge driven by recent analyst upgrades and encouraging clinical trial updates. The company, focused on breast canc...
Olema Pharmaceuticals plans to launch a public offering of common stock or pre-funded warrants, with TD Cowen acting as book-running manager. The offering is subject to market conditions and regulatory approvals.
Martin Shkreli announced shorting Olema Pharmaceuticals stock, criticizing the company's valuation in the SERD drug market. Despite Shkreli's stance, Olema's stock surged over 140% after positive phase 3 results from Roche's breast cancer study, with analysts raising price targets.
Olema Oncology presented promising Phase 1b/2 trial results showing palazestrant combined with ribociclib demonstrated encouraging progression-free survival and tolerability in ER+/HER2- metastatic breast cancer patients, supporting ongoing Phase 3 clinical trials.
Olema Oncology announced the selection of a 90 mg once-daily dose of palazestrant for its Phase 3 OPERA-01 monotherapy trial and OPERA-02 combination trial with ribociclib. The company will present a trial-in-progress poster for OPERA-01 at the ASCO 2025 Annual Meeting.
